<DOC>
	<DOCNO>NCT01399125</DOCNO>
	<brief_summary>The purpose study ass efficacy , safety , tolerability Exelon® patch patient probable AD ( MMSE 10-20 ) , order support plan regulatory submission registration Exelon transdermal patch China . The study design confirm non-inferiority efficacy Exelon patch ( target 10 cm² patch size ) versus Exelon capsule ( target 6.0 mg bid dose ) cognition , use Alzheimer 's Disease Assessment Scale-Cognitive Subscale ( ADAS-Cog ) .</brief_summary>
	<brief_title>A 24-Week Efficacy , Safety Tolerability Rivastigmine Patch Study Patients With Probable Alzheimer 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<criteria>Inclusion criterion : diagnosis dementia Alzheimer 's type accord Diagnostic Statistical Manual Mental Disorders , 4th edition ( DSMIV ) criterion ; clinical diagnosis probable AD accord NINCDS/ADRDA criterion . brain scan ( magnetic resonance imaging ( MRI ) compute tomography ( CT ) ) consistent diagnosis AD . The brain scan must perform within one year prior randomization ; MMSE score ≥ 10 ≤ 20 ; sufficient education able read , write , communicate effectively premorbid state ; reside someone community throughout study , live alone , contact primary caregiver everyday ; Exclusion criterion : advanced , severe , progressive , unstable infectious , metabolic , immune , endocrinologic , hepatic , hematological , pulmonary , cardiovascular , gastrointestinal , and/or urological condition may interfere efficacy safety assessment put patient special risk ; history current diagnosis medical neurological condition AD identify contribute cause patient 's dementia ; current diagnosis probable possible vascular dementia accord National Institute Neurological Disorders Stroke Association Internationale pour la Recherche et l'Enseignement en Neurosciences criterion ( NINDSAIREN ) ; score &gt; 4 Modified Hachinski Ischemic Scale ( MHIS ) ; current DSMIV diagnosis major depression , unless , opinion investigator , remission least 12 week ; Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>Alzheimer 's</keyword>
	<keyword>Rivastigmine</keyword>
	<keyword>Patch</keyword>
	<keyword>Dementia</keyword>
</DOC>